Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oyster Point Pharma (OYST)
NASDAQ:OYST
RESEARCH TOOLSreports
Holding OYST?
Track your performance easily
See the Price Targets and Ratings of:
OYST Analyst Ratings
Currently, no data available
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
OYST Stock 12 Month Forecast
There Are No Analyst Ratings for OYST In The Last 3 Months.
| Highest Price Target― | Average Price Target― | Lowest Price Target― |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
OYST Financial Forecast
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
$11
Hold
―
Downgraded
11/07/22
Piper Sandler Downgrades Oyster Point Pharma to Neutral, Lowers Price Target to $11
LifeSci Capital
$12
Hold
―
Assigned
11/07/22
This morning, Oyster Point Pharma (NasdaqGS: OYST) announced that it is being acquired by Viatris (NasdaqGS: in upfront cash with a $2/share CVR. This represents a deal value of ~$360M in upfront cash and up to ~$425M with full CVR achievement, a ~32-56% premium over Friday’s close of $8.35/share. The transacon is expected to close in Q1 2023. Notably, there are two CVR thresholds worth $1/share each, triggered at: 1) 2022 net product revenues of $21.6M AND 131,822 total Tyrvaya prescripons, and 2) 2022 net revenue of $24.0M AND 146,469 total Tyrvaya prescripons. Tyrvaya has ~107k scripts YTD, as highlighted in Figure 1. Thus, the first CVR threshold (purple line: 2022 net product revenues of $21.6M and 131,822 total Tyrvaya prescripons) appears potenally aainable. The more challenging aspect to achieving either CVR milestone is likely to be the net product revenue component.
Chardan Capital
$13
Hold
―
Downgraded
11/07/22
Chardan Capital Downgrades Oyster Point Pharma to Neutral, Lowers Price Target to $13
H.C. Wainwright
$20
Buy
―
Reiterated
08/12/22
Analysts' Top Healthcare Picks: Qiagen (QGEN), Oyster Point Pharma (OYST)
OYST Analyst Recommendation Trends
Currently, no data available
Please return soon. This page is being updated.
Each month's total comprises the sum of three months' worth of ratings.
OYST Stock Forecast FAQ
What is OYST’s average 12-month price target, according to analysts?
Currently, no data Available
What is OYST’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for OYST, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is OYST a Buy, Sell or Hold?
Currently, no data Available
What is Oyster Point Pharma’s price target?
Currently, no data Available
What do analysts say about Oyster Point Pharma?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of OYST?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.